MedTrace Logo

Safety and Immunogenicity of a Zoster Vaccine in SLE

NCT02477150 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2019-09-04

No results posted yet for this study

Summary

To study the safety and immunogenicity of a herpes zoster vaccine in patients with SLE.

Conditions

Interventions

BIOLOGICAL

Zostavax

Vaccination of a zoster vaccine (Zostavax)

BIOLOGICAL

placebo

placebo administration

Sponsors & Collaborators

  • Tuen Mun Hospital

    lead OTHER_GOV

Principal Investigators

  • CC Mok, MD · Tuen Mun Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2018-11-30
Completion
2019-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02477150 on ClinicalTrials.gov